Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Severe case 31% Improvement Relative Risk Severe case (b) 40% Severe case (c) 0% c19early.org/d Levitus et al. Vitamin D for COVID-19 Prophylaxis Is prophylaxis with vitamin D beneficial for COVID-19? Retrospective 129 patients in the USA Lower severe cases with vitamin D (not stat. sig., p=0.25) Levitus et al., J. the Endocrine Society, doi: 10.1210/jendso/bvab048.567 Favors vitamin D Favors control
The Effect of Vitamin D Supplementation on Severe COVID-19 Outcomes in Patients With Vitamin D Insufficiency
Levitus et al., Journal of the Endocrine Society, doi: 10.1210/jendso/bvab048.567
Levitus et al., The Effect of Vitamin D Supplementation on Severe COVID-19 Outcomes in Patients With Vitamin D Insufficiency, Journal of the Endocrine Society, doi: 10.1210/jendso/bvab048.567
May 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 129 hospitalized patients with vitamin D levels measured within 90 days prior to admission, showing lower, but not statistically significant, risk of severe cases with vitamin D supplementation among patients with levels <20ng/mL or <12ng/mL. For <30ng/mL, lower (but not statistically significant) risk was seen overall but not for ≥50,000IU (the sample size is not given, it may be extremely small for this case). Only minimal details for <30ng/mL are provided, and no details for <20ng/mL or <12ng/mL are provided. The potential effect of supplementation on the risk of a case severe enough for hospitalization is not included.
risk of severe case, 30.8% lower, RR 0.69, p = 0.25, treatment 65, control 64, odds ratio converted to relative risk, ≥1,000IU, control prevalence approximated with overall prevalence.
risk of severe case, 40.0% lower, RR 0.60, p = 0.15, treatment 65, control 64, odds ratio converted to relative risk, ≥5,000IU, control prevalence approximated with overall prevalence.
risk of severe case, no change, RR 1.00, p = 0.92, treatment 65, control 64, odds ratio converted to relative risk, ≥50,000IU, control prevalence approximated with overall prevalence.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Levitus et al., 3 May 2021, retrospective, USA, peer-reviewed, 9 authors, dosage varies.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: doi: 10.1210/jendso/bvab048 | Journal of the Endocrine Society | A279 aimed to determine whether vitamin D supplementation in vitamin D insufficient patients was associated with fewer severe COVID-19 outcomes, defined as mechanical ventilation or death. Methods: Retrospective study that analyzed data from all adult patients admitted to our tertiary care center between March 2020 and July 2020 with a positive RT-PCR for SARS CoV-2 and a serum 25-hydroxyvitamin D (25[OH]D) level measured within 90 days prior to the index admission. Patients with 25(OH)D <30 ng/mL were considered vitamin D insufficient and patients ordered for least one weekly dose of ≥1,000 units of ergocalciferol or cholecalciferol were considered supplemented. Supplemented vitamin D insufficient patients were compared to nonsupplemented vitamin D insufficient patients in terms of severe COVID-19 disease as defined by mechanical ventilation or death. Results: 129 COVID-19 patients with a vitamin D level <30 ng/mL were identified, with a median vitamin D level of 21.4 ng/mL. A total of 43 patients (33.3%) had severe COVID-19 outcomes. 65 (50.4%) patients with vitamin D insufficiency were supplemented and 64 (49.6%) were not supplemented. Vitamin D supplementation with ≥1,000 units (OR 0.6, 95% CI 0.28 - 1.40; p=0.25), ≥5,000 units (OR 0.5, 95% CI 0.26 - 1.23; p=0.15), or ≥50,000 units (OR 1.0, 95% CI 0.42–2.20, p=0.92) weekly had no statistically significant effect on severe COVID-19 outcomes. The odds of severe COVID-19 outcomes in supplemented patients were non-significantly reduced at lower cutoff values for vitamin D insufficiency (<20 ng/mL and <12 ng/ mL) for all supplementation amounts. Conclusion: Vitamin D supplementation in patients with vitamin D insufficiency did not significantly reduce severe COVID-19 outcomes; however, vitamin D supplementation was associated with non-statistically significant reduced odds of severe COVID19 outcomes at lower cutoff values of vitamin D level. These results demonstrate that Vitamin D supplementation may have a protective effect against severe COVID-19 outcomes in patients with lower baseline levels of vitamin D. Bone and Mineral Metabolism VITAMIN D, DIABETES AND ENERGY METABOLISM The Effect of Vitamin D Supplementation on Severe COVID-19 Outcomes in Patients With Vitamin D Insufficiency 1 Bone and Mineral Metabolism VITAMIN D, DIABETES AND ENERGY METABOLISM 2 Corinne Levitus, DO , Sweta Chekuri, MD , Andrei Assa, MD2, Laurel Mohrmann, MD2, Alexandra Zindman, MD3, Vafa Tabatabaie, MD1, Fabrizio Toscano, MD3, Masud Ahmed, PA-C2, Sarah W. Baron, MD2. 1 Albert Einstein College of Medicine and Montefiore Medical Center, Department of Internal Medicine, Division of Endocrinology, Bronx, NY, USA, 2Albert Einstein College of Medicine and Montefiore Medical Center, Department of Medicine, Division of Hospital Medicine, Bronx, NY, USA, 3Albert Einstein College of Medicine and Montefiore Medical Center, Department of Internal Medicine, Residency Training Program, Bronx, NY, USA. The Impact of Glucose Tolerance States on Bone Mineral Density and Fracture Rate Maria Chang Villacreses, MD1, panadeekarn panjawatanan, MD2, Rudruidee Karnchanasorn, MD3, Horng-Yih Ou, MD & PhD4, Wei Feng, MD5, Raynald Samoa, MD6, Lee-Ming Chuang, MD, PhD7, Ken C. Chiu, MD8. 1 CITY OF HOPE NATIONAL MEDICAL CENTER, Duarte, CA, USA, 2Bassett Medical Center, Cooperstown, NY, USA, 3The University of Kansas Medical Center, Kansas City, KS, USA, 4 National..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit